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Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac
conduction. Its well known common electrocardiographic effects are prolongation of PR
and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in
an elderly female who presented with a type 1 Brugada pattern who essentially had
a previously normal ECG pattern on therapeutic dose of flecainide therapy. The case
describes a rare electrocardiographic abnormality induced by flecainide toxicity which
otherwise could be easily misinterpreted as a ST-segment elevation myocardial infarction
(STEMI) without lack of expertise and high clinical suspicion.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Case report cardiac enzymes were within reference range except mildAn 86-year old female was brought to the hospital with
complaints of generalized weakness, decreased appetite and
mild confusion of 5 days duration. She also reported nausea,
mild epigastric and atypical chest discomfort relieved by
belching. Her past medical history included hypertension,
lower gastrointestinal bleeding and atrial fibrillation for which
she was started on flecainide (150 mg twice daily) 2 months
prior to the current presentation. Her echocardiogram done 2
months ago was unremarkable. Family history was noncon-
tributory. Initial vital signs were stable and physical exami-
nation was essentially unremarkable except mild cognitive
impairment. Her laboratory work-up including hemogram,
basic metabolic panel, liver function tests, urinanalysis andt, Apt 813, Worcester, MA
hhabra).
2012, Cardiological Socieelevation in her creatinine level (Cr ¼ 1.4 mg/dl) compared to
her baseline (Cr ¼ 1.0 mg/dl). An ECG at the admission time
demonstrated right bundle branch block (RBBB) like
morphology, coved type 3.5 mm ST elevation with T-wave
inversion in leads V1 and V2 consistent with a type 1 Brugada
pattern and a prolonged QRS duration [Fig. 1]. Her previous
ECG done a month prior on flecainide therapy was essentially
normal [Fig. 2]. The emergency room (ER) physician activated
the cardiac catheterization team for possible ST-elevation
myocardial infarction (STEMI) based on the ECG findings. A
prompt evaluation by the cardiology teamwas done in ER and
flecainide toxicity was suspected based on the ECG findings of
prolonged PR interval and QRS complex duration, absence of
reciprocal lead ST changes, negative cardiac biomarkers and01604, USA. Tel.: þ1 508 667 5052.
ty of India. All rights reserved.
Fig. 1 e Electrocardiogram on initial presentation
demonstrating a prolonged PR interval and QRS duration,
right bundle branch block morphology, coved type 3.5 mm
ST-segment elevation with T-wave inversion in leads V1
and V2 (type 1 Brugada like pattern).
Fig. 3 e ECG 6 h later revealed a bifascicular block pattern,
relative decrease in QRS duration and decreased ST
elevation to 2.5 mm in leads V1 and V2.
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arrhythmic drug toxicity. IV fluids with bicarbonate supple-
mentation were initiated and she was admitted to the cardiac
care unit for closer monitoring. Repeat ECG 6 h later revealed
a bifascicular block pattern, relative decrease in QRS duration
and decreased ST elevation to 2.5 mm in leads V1 and V2
[Fig. 3]. Another ECG 12 h later showed an incomplete RBBB
like morphology, normalization of the PR interval and QRS
duration and decreased ST elevation at 2 mm in leads V1 and
V2 consistent with a still persistent type 1 Brugada pattern
[Fig. 4]. Results of serum flecainide level drawn in the ER
returned the following day at 2350 mg/L (Therapeutic range:
200e1000 mg/L). On Day 2, she was asymptomatic and her
mental status returned to her baseline. An electrocardiogram
before discharge on Day 4 showed complete normalization
[Fig. 5]. Flecainide was discontinued and she was discharged
on diltiazem and aspirin as she had refused warfarin. An
outpatient clinic follow-up 4 weeks post-discharge showed
a normal ECG and also screening ECG’s obtained in five first-
degree relatives revealed no obvious abnormality for Bru-
gada pattern, including her 65 years old brother who had
a normal ECG on flecainide therapy for AF.2. Discussion
Flecainide is a class 1c antiarrhythmic drug (AAD) that blocks
sodium channels. Flecainide produces a dose-dependent
decrease in intracardiac conduction, but its effects on intra-Fig. 2 e Electrocardiogram 1 month prior to the current
presentation while patient was on therapeutic dose of
flecainide therapy.atrial and AV nodal conduction are less pronounced than
those on His-Purkinje conduction and ventricular activation.1
It prolongs the PR interval, the QRS complex duration and
some QT prolongation may also be noticed due to a widening
of the QRS complex, so that the JT interval and QTc remain
unchanged or slightly increase.1 ST elevation is an under
recognized electrophysiological abnormality induced by fle-
cainide which can often mimic an acute myocardial infarc-
tion.2,3 ST elevation with flecainide use can in fact be
associated with a Brugada like pattern as in our case.3,4
Previous studies have suggested that flecainide can induce
a new Brugada ECG pattern or can unmask a Brugada
syndrome by inducing a type 1 Brugada pattern in patients
with pre-existing type 2 or type 3 Brugada patterns.3e5 Drug-
induced Brugada pattern can be generally seen at standard
therapeutic dose of flecainide and such patients may have
a possible underlying genetic predisposition (like SCN5A
mutations) causing abnormality of native sodium channel
activity.3e6 Interestingly, our patient didn’t have any self or
family risk factors for Brugada syndrome and didn’t demon-
strate any electrocardiographic abnormality at baseline or on
therapeutic dose of flecainide but a type 1 Brugada pattern
with cove shaped ST elevation was revealed at the toxic dose
of flecainide which showed complete resolution after
discontinuation of flecainide therapy. Thus, our case likely
represents a complete iatrogenic induction of the type 1 Bru-
gada phenotype due to flecainide toxicity in a patient withoutFig. 4 e Electrocardiogram 12 h after presentation showed
an incomplete RBBB like morphology, normalization of the
PR interval and QRS duration and decreased ST elevation at
2 mm in leads V1 and V2 (representing persistent type 1
Brugada pattern).
Fig. 5 e Electrocardiogram prior to discharge showing
complete resolution of Brugada phenotype.
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would otherwise have had likely manifested at therapeutic
flecainide dose. The most likely explanation for this would be
that toxic dose of a sodium channel blocker like flecainide
may induce an iatrogenic sodium channel defect in a normal
individual similar to a patient with sodium channel genetic
defect like with “loss of function” mutation. Thus, an ST-
elevation related to Brugada pattern could occur selectively
at toxic dosing in any patient receiving flecainide therapy.
Because these drugs frequently are used to treat tachyar-
rhythmias in patients who may present with chest pain, this
rare ECGmanifestation of Class Ic drugs should be recognized
to avoid misdiagnosis of acute myocardial infarction. ER
physicians should maintain a high suspicion for flecainide
toxicity especially in elderly and patients with poor renal
function. With a good clinical history and high index of clin-
ical suspicion, an unnecessary intervention could be avoided
by the ER physicians as they form the foremost important part
of STEMI care measure protocol. Reiffel recently reported an
interesting case study where Brugada pattern was noted in
a patient who consumed a single 600 mg oral dose of flecai-
nide who otherwise had a normal ECG while not on flecainide
therapy.8 This observation raised the question as to whether
when administered as a diagnostic test, higher flecainide
doses than have been commonly used should be used, or,
alternatively, whether the response in his patient could be
a “false-positive” that might be seen in some normal indi-
viduals if exposed to this much flecainide.8 The answer to this
question however remained unclear probably because of
three reasons: there was no available ECG to compare while
the patient was on standard therapeutic flecainide dose, fle-
cainide level on the patient was not obtained for objective
confirmation and also genotype studywas not performed. The
patient in our case had several ECG’s in outpatient follow-up
after she was started on the standard therapeutic dose of
flecainide which were essentially normal, however Brugada
pattern was present at the toxic drug level which occurred
likely due to the drug-induced sodium channel defect
(although patient remained on standard flecainide dose).
There was gradual narrowing of the QRS complex which was
accompanied by a parallel reduction of the ST-segment
elevation with a delay of several hours. This finding suggests
that global reduction of the fast inward sodium current is the
primary electrophysiological defect and the repolarization
abnormality is secondary with a drug-induced Brugada signand confirms one of the previous observation reported by
Hudson et al9 The genotype study was not performed in our
case for the reason that it would be extremely unlikely for
a genetic Brugada syndrome to manifest for the first time at
the age of 86 years especially when patient previously had all
normal electrograms in her life including the ones obtained on
the standard therapeutic flecainide level. Thus, Brugada
pattern was specifically induced at a toxic level of flecainide
(though on the standard therapeutic dose) in the setting of
transient renal insufficiency in our patient who had no prior
risk factors of Brugada syndrome and when no electrocar-
diographic abnormality was seen earlier at standard thera-
peutic flecainide dose. Also, the screening ECG’s obtained in
first-degree relatives showed no abnormality including one
of her brothers on flecainide therapy. This case finding
suggests that a Brugada phenotype may serve as a standard
electrocardiographic sign for the drug toxicity and a high
suspicion for the same should be raised even in asymptomatic
patientswho are on standard therapeutic doses of such agents
and have tolerated them well in the past.3. Conclusion
ST-segment elevation can result from administration of class
1c drugs2e4,7 and should be considered as a differential in
patients receiving such drug agents. ST elevation is often seen
as a part of the drug-induced Brugada pattern in patients with
underlying sodium channel defect but can occur de novo even
in patients with no genetic defect receiving strong class 1c
agents like flecainide. Brugada pattern can selectively result
from a toxic dose of flecainide and in those patients who have
tolerated the therapeutic dose of flecainide well in the past
without any demonstrated electrocardiographic abnormality;
this electrocardiographic sign may represent drug toxicity.Conflicts of interest
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